What makes a focal hip cartilage defect different from arthritis

Being told you have a cartilage problem in your hip sounds alarming, but the clinical picture varies enormously — and the distinction matters when it comes to choosing treatment.

The hip is a ball-and-socket joint lined with hyaline cartilage, a smooth, resilient tissue that allows the femoral head and acetabulum to glide together under load. A focal cartilage defect means a discrete, full-thickness patch of that lining has worn through — typically a Grade III or IV lesion on the ICRS scale — while the surrounding cartilage remains largely intact. This is structurally quite different from diffuse osteoarthritis, where the whole joint surface has thinned and the underlying bone has begun to remodel.

In younger active adults, femoroacetabular impingement (FAI) is the most common mechanical cause. Repeated bony contact between the femoral head and acetabular rim chips away at the cartilage over months or years, eventually producing these contained defects.

Because hyaline cartilage has no blood supply or nerve fibres, it cannot repair itself spontaneously. That biological limitation places focal defects on a distinct clinical pathway — cartilage preservation — rather than the replacement pathway appropriate for advanced, diffuse wear. Practically, Tönnis grade 0–1 defines the realistic upper boundary for repair interventions; grade 2–3 joint changes shift the conversation toward hip replacement.

How microfracture works — and what it was designed to do

Microfracture dates from the 1990s and was the standard first-line surgical response to focal cartilage defects for roughly two decades. The technique is straightforward in concept: working through an arthroscope under general or spinal anaesthesia, the surgeon first removes any unstable cartilage fragments and trims the defect to a stable border, then uses a surgical awl to drill small perforations — typically spaced 3–4 mm apart — into the exposed subchondral bone beneath the lesion. A dry operative field is essential throughout, because fluid in the joint would prevent the subsequent repair clot from adhering.

Those perforations are the mechanism. Each hole breaches the bone's vascular layer, releasing bone marrow — and the mesenchymal stem cells it contains — into the defect cavity. Blood and marrow pooling from multiple perforation sites coalesce into a fibrin clot that acts as a biological scaffold, gradually maturing into repair tissue over the following weeks and months.

The tissue that forms is fibrocartilage rather than native hyaline cartilage. Fibrocartilage is a scar-like material — denser and less compliant than the original lining it replaces.

The procedure's appeal was practical: it is single-stage, performed within a standard arthroscopic setup, and technically reliable — qualities that made it the default for contained defects historically under 2 cm² in patients without other joint damage.

Why microfracture has largely been superseded in the hip

Three distinct problems explain why bare microfracture has lost ground as the default hip cartilage repair.

The first is biological. The fibrocartilage produced by marrow stimulation is softer and less resilient than native hyaline cartilage, and under the cyclical loading of normal hip use, evidence suggests it tends to break down within two to three years. Age makes the picture worse: a systematic review of marrow-stimulation studies found that patients in their forties and fifties gain only modest, largely short-lived benefit compared with younger recipients — a meaningful restriction given how many people with FAI-related focal defects fall into exactly that age range.

The second concern is structural. Perforating the subchondral bone plate is not a neutral step. Each hole introduces micro-damage to the bony layer that anchors the cartilage surface. Should microfracture fail and a subsequent procedure become necessary — an injectable scaffold, an osteochondral transfer, or a cell-based implant — that compromised plate can make follow-on repair more demanding and, in some cases, less viable.

Third, patient acceptance and anatomical prerequisites together limit reliable use. In a randomised controlled trial comparing ChondroFiller liquid against microfracture, six of the ten patients allocated to the surgical arm declined the procedure outright — a striking real-world signal of how bone-drilling under general or spinal anaesthesia lands when a clear alternative is available. Even among those willing to proceed, the technique depends on a mechanically stable hip. Hip stability matters considerably in practice, and a 2025 animal-model study helps illustrate why: preserving the labrum and capsule during femoral-head microfracture produced significantly superior cartilage repair quality — higher type II collagen and aggrecan expression — than the drilling step applied without those structural repairs. In the clinical setting, where labral damage commonly accompanies FAI-related defects, this anatomical prerequisite narrows the field of reliably suitable candidates.

Augmented marrow-stimulation variants — combining the perforation base with a scaffold layer or biologic graft — have shown better medium-term outcomes and remain a reasonable surgical pathway for carefully selected younger patients with good joint status. Their development is instructive: the field effectively accepted that bare microfracture was insufficient and moved to add the scaffold layer that injectable approaches now aim to provide without disturbing the subchondral bone.

How ChondroFiller injection works differently

Rather than breaching the bone to recruit repair cells from below, ChondroFiller injection works in the opposite direction — placing a collagen scaffold over the defect from above and letting the joint's own biology do the rebuilding.

In the current service pathway, ChondroFiller is delivered as an ultrasound-guided outpatient injection. There is no operating theatre, no general anaesthesia, and no surgical approach to the hip joint. The material is introduced into the joint under image guidance and settles across the area of cartilage loss.

The scaffold is an acellular Type I collagen hydrogel. Once positioned, it polymerises at body temperature into a three-dimensional matrix covering the defect site. The patient's own progenitor cells — drawn in from the surrounding synovium and the tissue bordering the lesion — migrate into this framework and progressively produce new cartilage matrix over roughly three to six months. This process is called matrix-induced chondrogenesis: the scaffold provides structure and a biological signal; the body supplies the cells. No separate cell harvesting is needed, and no bone is perforated.

Critically, the subchondral bone plate remains entirely undisturbed. Because microfracture's drilling step introduces micro-damage to that foundational layer — complicating any future repair — preserving it is a meaningful practical advantage. If circumstances change and a further procedure were ever needed, the structural foundation would still be intact.

One honest practical note: the scaffold requires time to integrate before the joint can be loaded normally. A period of protected weight-bearing after injection is a standard part of the protocol, and patients should plan for this before proceeding.

What the clinical evidence shows — and where gaps remain

The strongest hip-specific evidence for ChondroFiller comes from a prospective cohort published in the Journal of Hip Preservation Surgery in 2021. Of 26 adults with FAI and acetabular cartilage lesions larger than 2 cm², 17 of 21 evaluable patients — 81% — maintained good or excellent results at each of the 3-, 4-, and 5-year follow-up points. Patients who entered the study with pre-existing Tönnis grade 2–3 osteoarthritis fared poorly, reinforcing that the treatment is designed for focal, well-contained defects rather than diffuse joint degeneration.

A 2025 case report in the Journal of Orthopaedic Case Reports documented complete pain relief and normal gait in a 32-year-old man with a 15 mm × 5 mm femoral head lesion treated with ChondroFiller specifically without performing microfracture — the authors noting that the scaffold 'preserves the subchondral bone and eliminates the need for more invasive or staged procedures.' Across the broader published literature covering hip, knee, and small-joint applications, 70–85% of ChondroFiller-treated patients achieve meaningful symptom relief at three to five years.

For context on the augmented-microfracture middle ground: BioCartilage — combining allograft cartilage and autologous PRP over a drilled base — achieves 84–88% meaningful outcome thresholds in hip cohorts at both two and five years, with approximately one in ten patients ultimately requiring total hip replacement at both time points.

No randomised controlled trial has yet directly compared ChondroFiller injection against microfracture in the hip, and long-term data for the outpatient injectable route specifically remains awaited. Those are real gaps in an otherwise coherent body of evidence.

Which patients are suitable — and what rules both approaches out

Candidacy for either pathway rests on one fundamental prerequisite: a focal, well-contained defect with healthy cartilage at the lesion margins. Neither ChondroFiller injection nor microfracture reverses diffuse joint degeneration — Tönnis grade 2–3 osteoarthritis places a patient outside cartilage preservation and points toward a joint-replacement pathway instead.

To make that concrete: a 38-year-old with a 1.5 cm² acetabular lesion in a Tönnis grade 0–1 hip, with femoroacetabular impingement corrected or planned concurrently, sits within the range ChondroFiller injection is designed for. A 55-year-old with Tönnis grade 2 narrowing and widespread cartilage thinning does not — no scaffold changes that picture.

The FAI component deserves emphasis: if impingement is the mechanical driver of the defect and remains uncorrected, the repair tissue will continue to be stressed by the same abnormal contact regardless of which technique is used.

Age is particularly relevant where microfracture remains under consideration. Systematic review evidence suggests bone marrow stimulation produces only short-term benefit in patients aged 40–60 — a practical reinforcement of the shift toward scaffold-based approaches for that demographic.

Patients who cannot manage a period of protected weight-bearing after ChondroFiller injection — because of work demands, caring responsibilities, or mobility constraints — should raise this before any treatment decision, so that realistic timelines are agreed in advance rather than after the procedure.

For patients across Lincolnshire and the wider East Midlands, Lincolnshire Hip — part of the MSK Doctors group and accessible without GP referral — offers hip cartilage assessment at its Sleaford and Grantham clinics.

1. [1] Hip Arthroscopy and Chondrofiller Application in Isolated Osteochondral Defect of the Femoral Head. (2025). https://doi.org/10.13107/jocr.2025.v15.i10.6176 https://doi.org/10.13107/jocr.2025.v15.i10.6176
2. [2] Preserving Hip Stability Yields Better Cartilage Repair With Microfracture Treatment: A Rabbit Study. (2025). https://doi.org/10.1016/j.asmr.2025.101284 https://doi.org/10.1016/j.asmr.2025.101284
3. [3] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
4. [4] A Systematic Review of Focal Cartilage Defect Treatments in Middle-Aged Versus Younger Patients. (2021). https://doi.org/10.1177/23259671211031244 https://doi.org/10.1177/23259671211031244
5. [5] Patients Undergoing Microfracture With Allograft Cartilage and Autologous Platelet Rich Plasma Augmentation For Chondromalacia In The Hip Achieving High Rates Of Meaningful Outcomes At 2-Year Follow-Up. (2025). https://doi.org/10.1016/j.arthro.2025.01.022 https://doi.org/10.1016/j.arthro.2025.01.022
6. [6] Sustained benefit of autologous matrix-induced chondrogenesis for hip cartilage repair in a recreational athletic population. (2019). https://doi.org/10.1007/s00167-019-05801-y https://doi.org/10.1007/s00167-019-05801-y
7. [7] Hip Chondral Defects: Arthroscopic Treatment With the Needle and Curette Technique and ChondroFiller. (2021). https://doi.org/10.1016/j.eats.2021.03.011 https://doi.org/10.1016/j.eats.2021.03.011
8. [8] Rates of Achieving Meaningful Outcomes and Predictors of Clinical Failure 5-Years After Undergoing Microfracture Augmented with Allograft Cartilage For Treatment of Hip Chondral Defects. (2025). https://doi.org/10.1177/2325967125s00203 https://doi.org/10.1177/2325967125s00203